Published in the
Published in the Journal of Clinical Apheresis an open-label, pilot study of five patients with a mean SCORAD of 67.9. The study was looking at the initial effects of a single use IgE-selective immunoadsorber column for the treatment of severe atopic dermatitis.
The results: In this initial study, all patients had a sustained and clinically relevant improvement in atopic dermatitis with a decline in SCORAD that was associated with selectively depleting serum IGE levels.
In addition, the intervention was well tolerated with no severe adverse events leading to the authors conclusion of clinical efficacy, feasibility and safety in this study of IgE selective immunoadsorber study for atopic dermatitis.